Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06845865

Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure

Status
Recruiting
Phase
Study type
Observational
Enrollment
126 (estimated)
Sponsor
Direction Centrale du Service de Santé des Armées · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Multivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the possible causes of bacteremia, digestive translocation is the most probable but has not been formally proven to date. This translocation is made possible by the numerous cellular and metabolic alterations secondary to MVFS, which can lead to increased intestinal barrier permeability. Intestinal permeability is currently not systematically evaluated in clinical practice in humans. This increased intestinal permeability, associated with the presence of inflammatory markers and a septic state, has been studied in several animal models ranging from the fruit fly (Drosophila) to the mouse. These studies have shown a high risk of mortality associated with increased intestinal permeability. We propose to use this methodology in intensive care patients with at least one organ failure to investigate the link between increased intestinal permeability and survival chances.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTenteric dyed solutionOral administration of 0.5 mg/kg of body weight of food coloring dye

Timeline

Start date
2025-02-20
Primary completion
2029-02-01
Completion
2029-04-30
First posted
2025-02-25
Last updated
2025-05-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06845865. Inclusion in this directory is not an endorsement.